Literature DB >> 29609005

Decreased PD-1 expression on circulating CD4+T cell and PD-L1 expression on myeloid dendritic cell correlate with clinical manifestations in systemic juvenile idiopathic arthritis.

Li Cai1, Chenxing Zhang1, Jing Wu1, Wei Zhou2, Tongxin Chen3.   

Abstract

OBJECTIVES: Programmed cell death-1 (PD-1) and its ligand (PD-L1) mediate negative signal in autoimmune diseases. While little is known about its role in juvenile idiopathic arthritis (JIA). The study aimed to reveal the circulating cell profile and the relative PD-1/PD-L1 expression of JIA subsets, elucidating their underlying immunomodulatory mechanisms.
METHODS: We detected the circulating cells and the relative PD-1/PD-L1 signaling in 101 JIA patients and 50 controls by flow cytometry and analyzed their association with disease activity and clinical manifestations.
RESULTS: Different from other JIA types, active systemic JIA (sJIA) patients had lower percentage and count of CD4+T cells and lower PD-1 expression on them compared with healthy controls (P<0.05), active polyarthritis (P<0.05) and enthesitis-related arthritis (ERA) patients (P<0.05). Also, they had higher percentage and count of myeloid dendritic cell (mDC) and lower PD-L1 expression on mDC compared with healthy controls (P<0.05). Both PD-1 on CD4+T cell and PD-L1 on mDC were negatively correlated with JADAS-27 in sJIA patients (P<0.05). In addition, PD-1 expression on CD4+T cell was negatively associated with the number of involved joints (P<0.05) and PD-L1 on mDC was lower in patients with fever (P<0.01), which could further divide patients into two groups of different manifestations.
CONCLUSIONS: Our finding displayed decreased CD4+T cell, increased mDC and reduced PD-1/PD-L1 signal in sJIA PBMC comparing with other JIA subsets, which might be helpful in JIA differential diagnosis and responsible for distinct clinical manifestations via different mechanisms.
Copyright © 2018 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  JIA; PD-1/PD-L1; sJIA

Mesh:

Substances:

Year:  2018        PMID: 29609005     DOI: 10.1016/j.jbspin.2018.03.003

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  4 in total

1.  Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis.

Authors:  Artemis Koutsonikoli; Anna Taparkou; Polyxeni Pratsidou-Gkertsi; Vassiliki Sgouropoulou; Theodoros Dimitroulas; Maria Trachana
Journal:  Mediterr J Rheumatol       Date:  2020-06-01

2.  The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings.

Authors:  Stinne R Greisen; Tue W Kragstrup; Jesper Skovhus Thomsen; Kim Hørslev-Pedersen; Merete Lund Hetland; Kristian Stengaard-Pedersen; Mikkel Østergaard; Lykke Ørnbjerg; Peter Junker; Arlene H Sharpe; Gordon J Freeman; Malene Hvid; Søren K Moestrup; Ellen Margrethe Hauge; Bent Deleuran
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 8.786

3.  Identification of Key Biomarkers and Immune Infiltration in Systemic Juvenile Idiopathic Arthritis by Integrated Bioinformatic Analysis.

Authors:  Min Zhang; Rongxin Dai; Qin Zhao; Lina Zhou; Yunfei An; Xuemei Tang; Xiaodong Zhao
Journal:  Front Mol Biosci       Date:  2021-07-14

4.  Programmed Cell Death Protein-1 Upregulation in Response to SARS-CoV-2 in Juvenile Idiopathic Arthritis: A Case-Control Study.

Authors:  Violetta Opoka-Winiarska; Ewelina Grywalska; Izabela Korona-Głowniak; Izabela Morawska; Krzysztof Gosik; Anna Malm; Jacek Roliński
Journal:  J Clin Med       Date:  2022-07-13       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.